全文获取类型
收费全文 | 50544篇 |
免费 | 3164篇 |
国内免费 | 245篇 |
专业分类
耳鼻咽喉 | 628篇 |
儿科学 | 1167篇 |
妇产科学 | 1216篇 |
基础医学 | 7050篇 |
口腔科学 | 1497篇 |
临床医学 | 5553篇 |
内科学 | 10893篇 |
皮肤病学 | 797篇 |
神经病学 | 5003篇 |
特种医学 | 1761篇 |
外科学 | 6306篇 |
综合类 | 325篇 |
一般理论 | 44篇 |
预防医学 | 3598篇 |
眼科学 | 804篇 |
药学 | 3439篇 |
1篇 | |
中国医学 | 59篇 |
肿瘤学 | 3812篇 |
出版年
2023年 | 298篇 |
2022年 | 499篇 |
2021年 | 1143篇 |
2020年 | 745篇 |
2019年 | 979篇 |
2018年 | 1195篇 |
2017年 | 1069篇 |
2016年 | 1254篇 |
2015年 | 1309篇 |
2014年 | 1738篇 |
2013年 | 2504篇 |
2012年 | 3789篇 |
2011年 | 3979篇 |
2010年 | 2365篇 |
2009年 | 2155篇 |
2008年 | 3287篇 |
2007年 | 3591篇 |
2006年 | 3203篇 |
2005年 | 3260篇 |
2004年 | 2998篇 |
2003年 | 2796篇 |
2002年 | 2565篇 |
2001年 | 429篇 |
2000年 | 351篇 |
1999年 | 484篇 |
1998年 | 563篇 |
1997年 | 459篇 |
1996年 | 407篇 |
1995年 | 347篇 |
1994年 | 304篇 |
1993年 | 308篇 |
1992年 | 234篇 |
1991年 | 228篇 |
1990年 | 208篇 |
1989年 | 220篇 |
1988年 | 195篇 |
1987年 | 171篇 |
1986年 | 177篇 |
1985年 | 210篇 |
1984年 | 181篇 |
1983年 | 166篇 |
1982年 | 192篇 |
1981年 | 159篇 |
1980年 | 139篇 |
1979年 | 112篇 |
1978年 | 122篇 |
1977年 | 131篇 |
1976年 | 94篇 |
1975年 | 107篇 |
1974年 | 81篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
911.
De Luca G Suryapranata H Dambrink JH Ottervanger JP van 't Hof AW Zijlstra F Hoorntje JC Gosselink AT de Boer MJ 《American heart journal》2004,148(5):852-856
Background
Several studies have found that among patients with ST-elevation myocardial infarction (STEMI) treated by thrombolysis, female sex is associated with a worse outcome. The aim of this study was to investigate sex-related differences in clinical and angiographic findings and in long-term outcome in patients with STEMI treated with primary angioplasty.Methods
Our population is represented by 1548 consecutive patients with STEMI treated by primary angioplasty from April 1997 to October 2001. All clinical, angiographic, and follow-up data were prospectively collected.Results
Among 1548 patients, 353 were women (22.8%). Female sex was associated with more advanced age, higher prevalence of diabetes, hypertension, more advanced Killip class, longer ischemia time, and smaller vessel caliber. No difference was observed in terms of procedural success, postprocedural epicardial flow, myocardial perfusion, ST-segment resolution, and enzymatic infarct size. At 1-year follow-up, female sex was associated with a significantly higher 1-year mortality rate at univariate (9.3% vs 4.9 %, RR [95% CI] = 1.79 [1.14 to 2.8], P = .002) but not at multivariate analysis (RR [95% CI] = 1.41 [0.86 to 2.32], P = NS).Conclusions
This study shows that in patients with STEMI treated by primary angioplasty, women are associated with higher mortality rate in comparison with men, mainly because of their high-risk profile and angiographic features. Female sex did not emerge as an independent predictor of death. 相似文献912.
Shifren JL Rifai N Desindes S McIlwain M Doros G Mazer NA 《The Journal of clinical endocrinology and metabolism》2008,93(5):1702-1710
OBJECTIVE: Our objective was to compare the effects of oral vs. transdermal estrogen therapy on C-reactive protein (CRP), IL-6, E- and P-selectin, intercellular adhesion molecule (ICAM)-1 and vascular cell adhesion molecule-1, serum amyloid A, transferrin, prealbumin, IGF-I, SHBG, thyroxine-binding globulin (TBG), and cortisol-binding globulin (CBG) in naturally menopausal women. DESIGN: This was a randomized, open-label crossover clinical trial. A 6-wk withdrawal from prior hormone therapy (baseline) was followed in randomized order by 12-wk oral conjugated equine estrogens (CEEs) (0.625 mg/d) and 12-wk transdermal estradiol (E2) (0.05 mg/d), with oral micronized progesterone (100 mg/d) given continuously during both regimens. RESULTS: A total of 27 women enrolled, and 25 completed both treatment periods. Nine parameters changed significantly during oral CEE (median percent change from baseline; P value): CRP (192%; P <0.001); E-selectin (-16.3%; P = 0.003); P-selectin (-15.3%; P = 0.012); ICAM-1 (-5%; P = 0.015); transferrin (5.3%; P = 0.024); IGF-I (-30.5%; P < 0.001); SHBG (113%; P < 0.001); TBG (38%; P < 0.001); and CBG (20%; P < 0.001). With transdermal E2, only three parameters changed significantly and to a lesser degree: ICAM-1 (-2.1%; P = 0.04); IGF-I (-12.5%; P < 0.001); and SHBG (2.6%; P = 0.042). During oral CEE the intrasubject changes in CRP correlated strongly with the changes in serum amyloid A (r = 0.805; P < 0.001), and were only weakly associated with the changes in SHBG (r = 0.248; nonsignificant), TBG (0.430; P = 0.031), and CBG (r = 0.072; nonsignificant). The log-log relationship between CRP and IL-6 observed at baseline showed a parallel shift during oral CEE, suggesting an amplified hepatic response or a greater sensitivity to IL-6 stimulation. CONCLUSION: Compared with oral CEE, transdermal E2 exerts minimal effects on CRP and the other inflammation and hepatic parameters. 相似文献
913.
MEK kinase 1 activity is required for definitive erythropoiesis in the mouse fetal liver 总被引:1,自引:0,他引:1
下载免费PDF全文
![点击此处可从《Blood》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Bonnesen B Orskov C Rasmussen S Holst PJ Christensen JP Eriksen KW Qvortrup K Odum N Labuda T 《Blood》2005,106(10):3396-3404
914.
Craig I. Coleman Alexander G.G. Turpie Thomas J. Bunz Jan Beyer-Westendorf William L. Baker 《The American journal of medicine》2019,132(4):498-504
Background
We sought to evaluate the real-world effectiveness and safety of prolonged anticoagulation with rivaroxaban following a provoked venous thromboembolism.Methods
Using US MarketScan claims from November 2012 to March 2017, we identified adults with ≥1 primary hospitalization or emergency department diagnosis code for venous thromboembolism, a provoking (major or minor, persistent or transient) risk factor, at least 3 months of continuous rivaroxaban treatment, and ≥12 months of continuous insurance benefits prior to their qualifying venous thromboembolism. Patients were categorized as either continuing rivaroxaban or discontinuing anticoagulation (no anticoagulation or nonaspirin antiplatelet agents but may have received aspirin) after the initial 3 months of rivaroxaban treatment (index date). Differences in baseline covariates between cohorts were adjusted for using inverse probability-of-treatment weights based on propensity scores (absolute standardized differences <0.1 achieved for all covariates after adjustment). Twelve month incidences of recurrent venous thromboembolism or major bleeding were compared between cohorts using Cox regression (according to an intention-to-treat methodology) and reported as hazard ratios (HRs) with 95% confidence intervals (CIs).Results
Among patients experiencing a provoked venous thromboembolism and treated with rivaroxaban for the first 3 months (N=4,990), continued rivaroxaban use beyond 3 months (median [25%, 75% range duration of additional rivaroxaban use?=?3 [2, 5] months) was associated with a 44% (95% CI of 9%-66%) lower hazard of recurrent venous thromboembolism without altering major bleeding risk [HR of 0.87, 95% CI of 0.51-1.49] versus anticoagulation discontinuation (with or without aspirin use).Conclusions
Our study suggests continuing rivaroxaban after the initial 3 month period was associated with a decreased risk of recurrent venous thromboembolism. The observed reduction in recurrent venous thromboembolism with prolonged rivaroxaban use was not associated with a significant change in major bleeding risk. 相似文献915.
916.
Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia 总被引:5,自引:16,他引:5
下载免费PDF全文
![点击此处可从《Blood》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Tobin G Thunberg U Johnson A Thörn I Söderberg O Hultdin M Botling J Enblad G Sällström J Sundström C Roos G Rosenquist R 《Blood》2002,99(6):2262-2264
Recent studies on the immunoglobulin variable heavy chain (IgV(H)) genes have revealed that B-cell chronic lymphocytic leukemia (B-CLL) consists of at least 2 clinical entities with either somatically mutated or unmutated V(H) genes. We have analyzed the V(H) gene mutation status and V(H) gene usage in 119 B-CLL cases and correlated them to overall survival. A novel finding was the preferential use of the V(H)3-21 gene in mutated cases, whereas biased V(H)1-69 gene usage was found in unmutated cases as previously reported. Interestingly, the subset of mutated cases using the V(H)3-21 gene displayed distinctive genotypic/phenotypic characteristics with shorter average length of the complementarity determining region 3 and clonal expression of lambda light chains. In addition, this mutated subset showed significantly shorter survival than other mutated cases and a similar clinical course to unmutated cases. We therefore suggest that B-CLL cases with mutated V(H)3-21 genes may constitute an additional entity of B-CLL. 相似文献
917.
Stone AF Mendall MA Kaski JC Edger TM Risley P Poloniecki J Camm AJ Northfield TC 《Circulation》2002,106(10):1219-1223
918.
919.
Nienke R Biermasz Alberto M Pereira Jan W A Smit Johannes A Romijn Ferdinand Roelfsema 《Growth hormone & IGF research》2005,15(3):200-206
OBJECTIVE: Depot formulations of somatostatin analogues are increasingly used in the treatment of active acromegaly. A priori knowledge of the efficacy of these drugs in controlling GH excess is clinically relevant, because only approximately 60% of the patients respond with adequate control of GH (GH levels < 5 mU/L) and/or IGF-1 levels upon this treatment. Therefore, we assessed the acute responses of serum GH levels to a new octreotide test (intravenous administration of 50 microg) in 98 consecutive patients with active acromegaly and we measured the predictive value of this test for the efficacy of chronic octreotide-long acting repeatable (octreotide-LAR) treatment in 18 patients. DESIGN: Serum GH concentrations were measured before and at 20, 30, 45, 60, 90, 120, 150 and 180 min following 50 microg i.v. octreotide. The minimal achieved GH was used for analysis. Octreotide-LAR was individually titrated aiming at a normal serum IGF-I for age and a serum GH < 5 mU/L. The mean of 3-6 monthly serum GH and IGF-I measurements after individual dose adjustment was used for evaluating the efficacy of chronic therapy. RESULTS: Octreotide decreased GH levels to values below 5 mU/L in only 49% of unselected consecutive patients and the response was inversely related to basal GH levels. In patients with baseline GH above 50 mU/L, 50 microg i.v. octreotide reduced GH to < 5 mU/L in only 15% of cases (n = 41), whereas in patients with baseline GH levels below 50 mU/L this goal was achieved in 77% of cases. The fractional decrease in GH levels upon octreotide injection was similar in microadenomas and macroadenomas. The minimally achieved serum GH concentration during the intravenous octreotide test was a good predictor for the GH concentrations during long-term octreotide-LAR treatment as assessed in 18 patients. The intravenous octreotide test, using a minimal GH level of < 5 mU/L, had a sensitivity, positive and negative predictive value of 100% for prediction of GH suppression to below 5 mU/L during long term octreotide-LAR treatment. For predicting the response of IGF-I during long-term treatment, the test performed with a sensitivity of 73% and a positive predictive value of 73%. CONCLUSION: Intravenous octreotide reduces GH to concentrations < 5 mU/L in approximately 50% of consecutive patients with active acromegaly, which predicts a good response to chronic octreotide-LAR treatment. 相似文献
920.
Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant 总被引:8,自引:0,他引:8
Barkan AL Burman P Clemmons DR Drake WM Gagel RF Harris PE Trainer PJ van der Lely AJ Vance ML 《The Journal of clinical endocrinology and metabolism》2005,90(10):5684-5691
CONTEXT: In clinical practice, patients with acromegaly may be switched from therapy with long-acting somatostatin analogs to pegvisomant. The effect of changing therapies on glucose homeostasis and safety has not been reported. OBJECTIVES: The objectives of this study were to monitor changes in IGF-I levels, glycemic control, and safety, particularly liver function and tumor size. DESIGN: This was a multicenter, open-label, 32-wk trial study. SETTING: The study was performed at outpatient clinics. PATIENTS: Fifty-three patients with acromegaly previously treated with octreotide long-acting release (LAR) participated in this study. Intervention: Pegvisomant (10 mg/d) was initiated 4 wk after the last dose of octreotide LAR and was adjusted based on serum IGF-I concentrations at wk 12, 20, and 28. MAIN OUTCOME MEASURES: The main outcome measures were changes in IGF-I, glycosylated hemoglobin A1c (HbA1c), fasting plasma glucose, and safety during the first 12 wk after conversion. RESULTS: At the end of pegvisomant treatment, IGF-I was normalized in 78% of patients. At wk 32, median fasting glucose concentration and HbA1c were reduced (-1.4 mmol/liter and -0.4%, respectively; both P < or = 0.0001) in the study population. Improvements in glycemic control occurred in patients with normal IGF-I concentrations at wk 4 [n = 15; fasting glucose, -1.7 mmol/liter (P < or = 0.0001); HbA1c -0.2% (P = 0.03)]. Decreases in fasting glucose and HbA1c levels were observed in patients with and without diabetes. HbA1c was reduced by more than 1.0% in patients with diabetes. Median pituitary tumor volume did not change, although tumor volume increased in two patients with macroadenomas. CONCLUSIONS: Conversion from octreotide LAR to pegvisomant was safe and well tolerated. Improved glycemic control indicates that pegvisomant should be considered in patients with acromegaly and diabetes. 相似文献